2023-12-18 17:04:45 Extension of the price regulation for biosimilars as an interim goal Vienna (OTS) – The National Council decided – just in time before the deadline – to extend the price regulation for biosimilars (successor products to complex biological drugs) for the next two years. By extending the price rule, security of supply for … Read more
2023-12-14 10:30:00 They are one step ahead and want to make it known. The Danish laboratories established industrially in France, Novo Nordisk, Coloplast, Leo Pharma, Lundbeck and ALK Pharma, form the Franco-Danish Health Alliance. An association intended to bring together manufacturers who share a solid industrial installation in France, since these laboratories represent 4,000 employees … Read more
2023-12-15 15:00:00 Vertex signs licensing agreement with Editas Medicine Vertex has just signed a licensing agreement with the American biotech Editas Medicine for its Cas9 gene editing technology, CRISPR scissors. This agreement includes Casgevy (exagamglogene autotemcel), a cell therapy from Vertex approved in early December by the FDA against sickle cell disease. Thanks to this … Read more
2023-12-13 22:31:44 Rauch’s low-level attacks on the FPÖ health spokesman have no basis Vienna (OTS) – “The Green Minister is also risking the health of people in Austria when it comes to the supply of medicines,” said FPÖ health spokesman NAbg today. Gerhard Kaniak was convincing and supported his criticism by looking at the list … Read more
2023-12-11 09:00:00 Leem has just announced the signing of a sector agreement for the ecological transition. What are the objectives pursued by this agreement? Pascal Le Guyader : The objective is to engage the entire sector in the field, starting with decarbonization. This is the momentum we wanted to give with this agreement, signed by … Read more
2023-12-11 13:00:00 Merck KGaA provided an update on phase III studies evaluating evobrutinib for the treatment of relapsing multiple sclerosis (MS). Neither trial met its primary endpoints. Among these criteria, the reduction in annualized relapse rates compared to oral teriflunomide, the reference treatment. “With evobrutinib, our goal was to address the significant unmet need in … Read more
2023-12-08 07:00:00 «20 years ago we only talked about tragedies and deaths», recalls Laurence Tiennot-Herment when she took over as president of the AFM-Téléthon. Since 2018, she has been delighted “a real acceleration of results and victories“. Thanks to donations, Généthon, the association’s laboratory, has enabled revolutionary breakthroughs in the understanding and even treatment of … Read more
2023-12-01 07:55:00 What remains of the unprecedented production effort launched during the Covid-19 pandemic? In 2021, CDMOs benefited from an unprecedented spotlight during the health crisis, with the production of the mRNA vaccine. Two years later, the record volumes requested to cope with the massive vaccination campaigns fizzled out. And push subcontractors to adapt. Latest … Read more